75N95024Q00198 - CSS.pdf

NON-COMPETITIVE

COMBINED SYNOPSIS / SOLICITATION

Title: dCas9-KRAB Cell Lines

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued.

(ii) The solicitation number is 75N95024Q00198 and the solicitation is issued as a request for quotation (RFQ).

This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures;

and FAR Part 12—Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold.

THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS

SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT

PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).

The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the

National Center for Advanced Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to the following for the acquisition of six (6) dCas9-KRAB cell lines:

Cellecta, Inc.

320 Logue Avenue, Mountain View, CA 94043

This acquisition is conducted as non-competitive for a commercial item or service and is conducted pursuant to FAR 13.106-1(b)(1).

The rationale for the sole source justification is that Cellecta has the ability to pick the cell line and modifications for CRISPR-mediated engineering and can validate both cell pools and clonal cell lines. Lastly, once the dCas9-KRAB cell lines are made, Cellecta will functionally validate the CRISPRi activity. Cellecta is the only vendor that has the capability to do these tasks listed, and awarding another vendor may compromise the validity or continuity of ongoing studies at NCATS.

(iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) Number 2024-03, with effective date

2/23/2024.

(iv) The associated NAICS code is 541380 – Testing Laboratories and Services and the small business size standard is $19.0 million. This requirement is non-competitive with no set-aside restrictions.

(v) This requirement is for the following services:

The National Institutes of Health has established an RNAi/CRIPSR Cas9 screening facility to provide intramural researchers with access to the equipment and expertise necessary to conduct genome-wide RNAi/ CRIPSR Cas9 screens in mammalian cells.

The NCATS Functional Genomics Lab requires six (6) dCas9 cell lines that will be used to repress the target gene expression when applied in a CRISPRi screen. See attached

Statement of Work.

(vi) The Government anticipates award of a firm fixed-price purchase order for this acquisition, and the anticipated period of performance is approximately 12 weeks, from

4/3/2024- 6/26/2024.

(vii) The provision at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb

1998), applies to this acquisition. This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text.

Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at these addresses:

https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html

(End of provision)

The following provisions apply to this acquisition and are incorporated by reference:

• FAR 52.204-7, System for Award Management (Oct 2018)

• FAR 52.204-16, Commercial and Government Entity Code Reporting (Aug 2020)

• FAR 52.212-1, Instructions to Offerors-Commercial Products and Commercial

Services (Sep 2023)

• FAR 52.212-3, Offeror Representations and Certifications-Commercial Products and Commercial Services (Feb 2024)

• HHSAR 352.239-78, Information and Communication Technology Accessibility

Notice (March 1, 2024)

The clause at FAR 52.252-2, Clauses Incorporated by Reference (Feb 1998), applies to this acquisition. This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting

Officer will make their full text available. Also, the full text of a clause may be accessed electronically at these addresses:

(End of clause)

The following clauses apply to this acquisition and are incorporated by reference:

• FAR 52.204-13, System for Award Management Maintenance (Oct 2018)

• FAR 52.204-18, Commercial and Government Entity Code Maintenance (Aug

2020)

• FAR 52.212-4, Contract Terms and Conditions-Commercial Products and

Commercial Services (Nov 2023). Addendum to this FAR clause applies to this acquisition and is attached.

• HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity

Investigations (December 18, 2015)

• HHSAR 352.239-78, Information and Communication Technology Accessibility

Notice (March 1, 2024)

The following provisions and clauses apply to this acquisition and are attached in full text. Offerors MUST complete the provisions at 52.204-24 and 52.204-26 and submit completed copies as separate documents with their proposal.

• FAR 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Nov 2021)

• FAR 52.204-26 Covered Telecommunications Equipment or Services- Representation (Oct 2020)

• FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or

Executive Orders-Commercial Products and Commercial Services (Feb 2024)

• NIH Invoice and Payment Provisions

(viii) The Government will evaluate quotations or offers in accordance with FAR 13.106-2 and award a purchase order from this solicitation to the responsible offeror whose quote conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate quotes:

a. Technical capability of the item offered to meet the Government requirement;

b. Price; and

c. Past performance [see FAR 13.106-2(b)(3)].

(ix) Offerors must include a completed copy of the provision at FAR clause 52.212-3, Offeror

Representations and Certifications-Commercial Items (Feb 2024), with its offer. If the offeror has completed FAR clause 52.212-3 at www.sam.gov, then the offeror does not need to provide a completed copy with its offer.

(x) There are no additional contract requirements or terms and conditions applicable to this acquisition.

(xi) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement.

(xii) Responses to this solicitation must include clear and convincing evidence of the offeror’s capability of fulfilling the requirement as it relates to the technical evaluation criteria. The price proposal must include the unit price and total price for all six (6) cell lines.

This synopsis is not a request for competitive quotations. However, interested parties may identify their interest and capability to respond to this notice. Responses to this solicitation must include sufficient information to establish the interested parties’ bona-fide capabilities of providing the product or service. A determination by the Government whether to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered to determine whether to proceed on a non-competitive basis as indicated above, or to conduct a competitive procurement.

The Unique Entity ID from SAM.gov, the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

All quotations must be received by 4:00 p.m., Eastern Time, on Friday, March 22, 2024, and reference solicitation number 75N95024Q00198. Responses must be submitted electronically to Sarah Adan, Contracting Officer at sarah.adan@nih.gov.

Fax responses will not be accepted.

http://www.sam.gov/ http://www.sam.gov/